2024 North-South Summit丨Professor Jia Wang: Should Contralateral Prophylactic Mastectomy Be Considered for gBRCA-Mutated Breast Cancer?

2024 North-South Summit丨Professor Jia Wang: Should Contralateral Prophylactic Mastectomy Be Considered for gBRCA-Mutated Breast Cancer?

2024.05.28
Among breast cancer patients, 5% to 10% have definite genetic mutations, with gBRCA1/2 mutations accounting for 15% of these cases. Individuals with gBRCA1 mutations have a higher risk of contralateral breast cancer recurrence, making the decision to undergo contralateral prophylactic mastectomy (CPM) a hot topic of discussion. At the 2024 North-South Summit, Professor Jia Wang from The Second Affiliated Hospital of Dalian Medical University delivered a report titled "gBRCA-Mutated Breast Cancer: Should Contralateral Prophylactic Mastectomy Be Considered?" This article reviews the content of the lecture.
Professor Ting Luo: Feasibility of Sequential ADC Treatment in Advanced Breast Cancer: ADC After ADC?丨2024 North-South Meeting

Professor Ting Luo: Feasibility of Sequential ADC Treatment in Advanced Breast Cancer: ADC After ADC?丨2024 North-South Meeting

2024.05.28
With the continuous development and market release of new ADC drugs, the treatment landscape for breast cancer patients has changed. For patients with advanced breast cancer, the feasibility of using another ADC drug after the initial ADC treatment has become a common clinical concern. In the "In-depth Inquiry" segment of the 2024 North-South Meeting, Professor Ting Luo from West China Hospital of Sichuan University delivered a report titled "Rescue Treatment for Advanced Breast Cancer: ADC After ADC?". This article reviews the content of her lecture.
EAU24 International Perspective丨Professor Thomas Powles: ADC Combined with Immunotherapy Poised to Reshape Urothelial Carcinoma Treatment

EAU24 International Perspective丨Professor Thomas Powles: ADC Combined with Immunotherapy Poised to Reshape Urothelial Carcinoma Treatment

2024.05.27
Urothelial carcinoma is one of the most common malignancies of the urinary system, with high incidence and mortality rates. Despite the efficacy of platinum-based chemotherapy as the standard first-line treatment for advanced urothelial carcinoma, researchers have been relentless in their pursuit of more effective and personalized treatment options. Recent breakthroughs in targeted therapies and immunotherapies have spurred the development of various combination therapies, bringing new hope to patients with advanced urothelial carcinoma. At the recently concluded 39th Annual Congress of the European Association of Urology (EAU24), Oncology Frontier had the privilege of interviewing Professor Thomas Powles from the University of London and Barts Cancer Institute. In this interview, Professor Powles detailed the current status and challenges in the field of advanced urothelial carcinoma, as well as future directions worth exploring.
2024 South-North Forum | Prof. Li Ma: Is Robotic Surgery Necessary for Early-Stage Breast Cancer?

2024 South-North Forum | Prof. Li Ma: Is Robotic Surgery Necessary for Early-Stage Breast Cancer?

2024.05.27
The prevalence of robotic surgery in the treatment of early-stage breast cancer is not high, and there is significant debate over its necessity for these patients. At the 2024 South-North Forum, Prof. Li Ma from The Fourth Hospital of Hebei Medical University delivered a presentation on the topic "Is Robotic Surgery Necessary for Early-Stage Breast Cancer?" This article reviews the key points from his lecture.
EAU24 Expert Review | Professor Qiang Wei: Multimodal Treatment of Renal Cancer from a Surgical Perspective

EAU24 Expert Review | Professor Qiang Wei: Multimodal Treatment of Renal Cancer from a Surgical Perspective

2024.05.27
The treatment of renal cancer includes surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. With advancements in treatment technologies, combining the latest modalities for comprehensive treatment of renal cancer is crucial for improving prognosis. The 39th Annual European Association of Urology (EAU24) Congress was held from April 5-8, 2024, in Paris, France, focusing on global urological oncology hotspots and forefront advancements from Chinese urological scholars. "Oncology Frontier" had the opportunity to interview Professor Qiang Wei from West China Hospital, Sichuan University, who shared insights into adjuvant immunotherapy for renal cancer, cytoreductive nephrectomy research, and robot-assisted radical nephrectomy.
Professor Wenbin Qian: Mechanisms of CAR-T Cell Therapy Resistance and Countermeasures | 2024 Nanjing Lymphoma Forum

Professor Wenbin Qian: Mechanisms of CAR-T Cell Therapy Resistance and Countermeasures | 2024 Nanjing Lymphoma Forum

2024.05.27
Chimeric Antigen Receptor T-cell Therapy (CAR-T) is a novel cellular immunotherapy technology that has shown excellent efficacy in the treatment of refractory relapsed diffuse large B-cell lymphoma (DLBCL). Despite this, a significant number of patients do not respond to the treatment or experience relapse and progression. How to further improve the efficacy of CAR-T cells is a key focus of future research. At the recently held "2024 Nanjing Lymphoma Forum," Professor Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine delivered a brilliant report titled "Mechanisms of CAR-T Resistance Based on DLBCL Pathological Characteristics and Countermeasures." After the conference, "Oncology Frontier - Hematologie Frontier" invited Professor Wenbin Qian for an interview to further discuss this topic.
Effectiveness and Safety of Direct Oral Anticoagulants in the Treatment of Visceral Vein Thrombosis

Effectiveness and Safety of Direct Oral Anticoagulants in the Treatment of Visceral Vein Thrombosis

2024.05.26
The "Hepatology Digest - Liver Vascular Diseases" column is a scholarly column co-initiated by Dr. Xingshun Qi from the Department of Gastroenterology at the General Hospital of Northern Theater Command, at the invitation of the editorial board of Hepatology Digest. This column regularly collects and summarizes research progress in the field of liver vascular diseases, selecting and discussing one significant paper every two weeks (Wednesday). The aim is to help readers understand the reasoning behind the findings, inspire clinical research thinking, and apply what they have learned in practice.
Hepatol Int | 24-Hour Comprehensive Lifestyle Interventions Help Prevent and Control MAFLD

Hepatol Int | 24-Hour Comprehensive Lifestyle Interventions Help Prevent and Control MAFLD

2024.05.26
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide, with recent data showing prevalence rates of up to 39% in adults and 20% in children. MAFLD is characterized by overweight or obesity, type 2 diabetes, and/or metabolically dysregulated hepatic steatosis and can coexist with various hepatic and cardiovascular metabolic diseases.
Prof. Pengfei Qiu: Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?

Prof. Pengfei Qiu: Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?

2024.05.26
The axillary lymph node burden after neoadjuvant therapy is closely related to prognosis. Unlike the assessment in initial surgery patients, residual tumor cells after neoadjuvant therapy are considered resistant cells. Thus, can limited sentinel lymph node biopsy (SLNB) metastasis after neoadjuvant therapy exempt patients from axillary lymph node dissection (ALND)? At the 2024 South-North Forum, Prof. Pengfei Qiu from Shandong Cancer Hospital presented a report titled "Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?" This article reviews the key points of his lecture.
Professor Yuqian Sun: Advances in Salvage Treatment for Primary Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Graft Failure

Professor Yuqian Sun: Advances in Salvage Treatment for Primary Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Graft Failure

2024.05.26
Graft failure is a rare but fatal complication following haploidentical allogeneic hematopoietic stem cell transplantation. A second transplant is almost the only salvage measure for transplant failure. However, outcomes from second transplants have generally been poor, as reported in previous literature. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with blood disorders. At this conference, a team led by Professor Yuqian Sun from Peking University People's Hospital presented their findings in an oral report titled "Salvage Haploidentical Transplantation with Flu/Cy Regimen and Donor Switching After Primary Graft Failure: Follow-Up Results," which garnered significant attention. Professor Sun was invited to share the main results of this study and the progress in salvage treatments for graft failure after haploidentical allogeneic hematopoietic stem cell transplantation.